Brain Injury |
|
|
Clinical Trial: Efficacy and Safety of Dexanabinol in Severe Traumatic Brain Injury Deaxanabinol in Traumatic Brain Injury
This study has been completed.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Traumatic Brain Injury | Drug: Dexanabinol | Phase III |
MedlinePlus related topics: Head and Brain Injuries
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Efficacy and Safety Evaluation of a Single Intravenous Dose of Dexanabinol in Patients Suffering from Severe Traumatic Brain Injury.
Secondary Outcomes: GOSE at 3 months; Mortality Rates at 10 days ansd 6 months; Intracerebral Pressure during first 72 houirs of trauma.; Neuroworsening at 10 days; Quality of Life
Expected Total Enrollment: 860
Study start: January 2001; Study completion: November 2004
Last follow-up: September 2004; Data entry closure: November 2004
Eligibility
Inclusion Criteria:
Traumatic head injury within the last 6 hrs.; Glasgow Coma Motor Score of 2 to 5;severity requires ICP monitoring;brain CT showing intracranial paranchymal abnormality and hemodynamically stable. An informed consent-
Exclusion Criteria:
Penetrating head injury Spinal cord injury Coma due to pure epidural hemayoma with initial GCS of=>12 Previous major cerebral damage - Concomtant Severe conditions
Location Information
Andrew Maas, M.D., Study Chair, Dep. of Neurosurgery,Dijkzigt Hospital,Rotterdam, Holland
More Information
Last Updated: August 11, 2005
Record first received: August 11, 2005
ClinicalTrials.gov Identifier: NCT00129857
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Resources
- Brain Injury (Centers for Disease Control and Prevention)
- Brain Injury (National Institute of Neurological Disorders and Stroke)

Not Signed In -

